10,937 Shares in CRISPR Therapeutics AG $CRSP Purchased by WCG Wealth Advisors LLC

WCG Wealth Advisors LLC purchased a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 10,937 shares of the company’s stock, valued at approximately $574,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rothschild Investment LLC boosted its position in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after buying an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. boosted its position in shares of CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after buying an additional 382 shares during the period. Optiver Holding B.V. boosted its position in shares of CRISPR Therapeutics by 71.4% during the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after buying an additional 210 shares during the period. Strategic Advocates LLC purchased a new position in shares of CRISPR Therapeutics during the third quarter valued at approximately $34,000. Finally, Oakworth Capital Inc. purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $34,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on CRSP shares. Citigroup restated a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Wednesday, May 27th. Truist Financial upgraded CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Sanford C. Bernstein boosted their target price on CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. TD Cowen boosted their target price on CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Finally, Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $65.47.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 10,020 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $468,735.60. Following the completion of the sale, the chief executive officer owned 255,501 shares in the company, valued at approximately $11,952,336.78. The trade was a 3.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 3,182 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $148,853.96. Following the completion of the transaction, the general counsel directly owned 94,308 shares of the company’s stock, valued at $4,411,728.24. This trade represents a 3.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 46,535 shares of company stock worth $2,311,300. Company insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Stock Down 9.0%

Shares of NASDAQ CRSP opened at $51.84 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97. The firm has a market capitalization of $5.00 billion, a price-to-earnings ratio of -8.33 and a beta of 1.74. The stock has a 50 day moving average price of $52.03 and a 200 day moving average price of $53.14. CRISPR Therapeutics AG has a 52-week low of $39.58 and a 52-week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. The firm had revenue of $1.46 million during the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. Sell-side analysts expect that CRISPR Therapeutics AG will post -4.92 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.